Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 3, 2000, Pages 233-240

  Vermeer, Frank ^a   Vahanian, Alec ^b   Fels, Phonse W ^c   Besse, Pierre ^d   Müller, Evert ^e   Van De Werf, Frans ^f   Fitzgerald, Detmond ^g   Darius, Harald ^h   Puel, Jean ⁱ   Garrigou, Desirée ^j   Simoons, Maarten L ^k  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL TENON   (France)

^c Drechtsteden Ziekenhuis   (Netherlands)

^d Ctr Geriatrie Ctr Hosp Univ B   (France)

^e Infection and Immunology   (Netherlands)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ CHU PURPAN   (France)

^j SANOFI   (France)

^k ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Alteplase; Angiography; Argatroban; Reocclusion; Thrombin inhibitor

Indexed keywords

ALTEPLASE; ARGATROBAN; HEPARIN;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ADULT; AGED; ANGIOGRAPHY; ARTERY OCCLUSION; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; ANGIOGRAPHY; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; PLASMINOGEN ACTIVATORS; SURVIVAL RATE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 17744378555     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026591023462     Document Type: Article

References (35)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
2. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
3. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase?
4. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: Five year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands
5. Reocclusion: The flip side of coronary thrombolysis
6. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST segment elevation
7. Initial experience with a direct antithrombin, hirulog, in unstable angina: Anticoagulant, antithrombotic and clinical effects
8. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa investigators: A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
9. Recombinant hirudin and front loaded alteplase in acute myocardial infarction: Final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis)
10. Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results
11. Hirudin in acute Myocardial infarction. Safety report from the thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
12. Randomized double blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
13. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
14. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
15. Bleeding risk with platelet inhibition using tirofiban: The RESTORE trial
16. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
17. RAPPORT
18. Combined therapy with streptokinase and integrilin
19. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrelin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial. IMPACT-AMI investigators
20. TIMI 14, preliminary results
21. Combined administration of aspirin and a specific thrombin inhibitor in man
22. Pharmacodynamic and pharmacokinetic profile of argatroban in healthy volunteers
23. Effects of the synthetic thrombin inhibitor argatroban on fibrinor clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
24. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805)
25. Argatroban, a selective, potent thrombin inhibitor
26. The preclinical and clinical pharmacology of Novastan (argatroban): A small-molecule, direct thrombin inhibitor
27. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effect on the tail transection bleeding time
28. Effects of argatroban, a specific thrombin inhibitor, in a canine model of coronary artery thrombosis
29. Effects of a 24-hour infusion of argatroban in healthy volunteers
30. Evidence of a rebound phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
31. The efficacy of argatroban in the prevention of reocclusion and restenosis after reperfusion therapy in patients with acute myocardial infarction
32. A multicentre, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: Myocardial infarction with novastan and tPA (MINT) study
33. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction
34. AMI angiographic reperfusion study. Argatroban as adjunctive therapy to streptokinase
35. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study